A Phase 1 study of DSP-3905 for neuropathic pain in the U.S
Latest Information Update: 30 Oct 2023
At a glance
- Drugs DSP 3905 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- Sponsors Sumitomo Pharma
Most Recent Events
- 30 Oct 2023 New trial record
- 25 Oct 2023 According to a Sumitomo Pharma media release, a Phase 1 study for neuropathic pain in the U.S. has been completed.